Categories Earnings, Health Care

Bristol-Myers Squib (BMY) set to report Q4 earnings – what is in the offing?

After closing the high-value acquisition of Celgene a few months ago, Bristol-Myers Squib (NYSE: BMY) will be publishing its fourth-quarter results on Thursday before the opening bell. The pharma firm is expected to report earnings of $0.94 per share, which is unchanged from the year-ago period. Analysts are looking for a 4% increase in revenues to $6.19 billion.

Bristol-Myers Squibb (BMY) earnings: Q3 results beat amid strong product sales

When the company releases the report, all eyes would be on the performance of products added to Bristol’s portfolio pursuant to the Celgene buyout, with the potential contributors being cancer drug Revlimid that witnessed double-digit sales growth in the third quarter. Celgene’s anemia drug Reblozyl, which was approved for additional indications a few months ago, is expected to have performed well this time.

Opdivo in Focus

Like in the past, the key revenue driver will be Bristol’s immuno-oncology drug Opdivo, which has been approved for additional use in the treatment of hepatocellular carcinoma, melanoma, and renal cell carcinoma. Among others, blood thinner drug Eliquis is estimated to have maintained the strong performance. The other promising products are Orencia (arthritis) and oncology drug Sprycel.


These positive factors will likely be partially offset by weakness in the mature products and virology businesses. Investors will also be looking for updates on the ongoing clinical trials of Opdivo, which keeps expanding market share outside the U.S. However, the recent withdrawal of EU application for Opdivo, in advanced non-small cell lung cancer, has come as a setback for the drug.

Q3 Performance

Earnings, excluding one-off items, increased to $1.17 per share and topped the estimates in the third quarter, reflecting the continued strong growth in product sales. At $6 billion, total revenue was higher by 6% from the year-ago period. Sales of Opdivo came in at $1.8 billion.

Merck & Co. (MRK) this week reported mixed results for its December-quarter. Earnings increased in double-digits to $1.16 per share and topped the Street view, while revenues missed. The company’s stock dropped after the announcement, reflecting the unimpressive top-line performance and weak guidance.

Related: Bristol-Myers Q3 2019 Earnings Conference Call Transcript

After falling to a six-year low in mid-2019, Bristol shares have been on a steady uptrend and gained 46% since then. The stock moved up 29% in the past twelve months.

Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips

Most Popular

What to expect when eBay (EBAY) reports Q4 2023 earnings

Shares of eBay Inc. (NASDAQ: EBAY) stayed red on Tuesday. The stock has gained 9% over the past three months. The ecommerce company is scheduled to report its earnings results

Earnings: Walmart (WMT) Q4 results beat estimates; revenues up 5.7%

Retail giant Walmart Inc. (NYSE: WMT) on Tuesday reported higher adjusted earnings and revenue for the fourth quarter of 2024. The numbers also came in above the consensus estimates. Fourth-quarter

Home Depot (HD) Q4 2023 Earnings: Key financials and quarterly highlights

Home Depot (NYSE: HD) reported fourth quarter 2023 earnings results today. Sales were $34.8 billion, down 2.9% from the same quarter a year ago. Comparable sales decreased 3.5%.  Net earnings were $2.8

Add Comment
Viewing Highlight